Robert Comp, MD
Pulmonary Disease · Phoenix, AZNPI 1588617724
Payments from drug & device makers
Across 435 payments — averaging $20.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$1K
- Sanofi$761
- Boehringer Ingelheim$731
- Insmed, Inc.$487
- Regeneron Healthcare Solutions, Inc.$366
- plus $4K from 38 others
What the payments were for
- Food & beverage$8,876100%
- Education$420%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 107 | $1,444 |
| AstraZeneca | 41 | $1,429 |
| Sanofi | 33 | $761 |
| Boehringer Ingelheim | 32 | $731 |
| Insmed, Inc. | 23 | $487 |
| Regeneron Healthcare Solutions, Inc. | 15 | $366 |
| Pulmonx Corporation | 14 | $276 |
| Baxter Healthcare | 14 | $258 |
| Genentech USA, Inc. | 14 | $251 |
| Inari Medical, Inc. | 1 | $243 |
| Mylan Specialty L.p. | 11 | $225 |
| Amgen | 11 | $219 |
| Electromed, Inc. | 18 | $219 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $188 |
| Philips North America LLC | 9 | $175 |
| Actelion Pharmaceuticals US, Inc. | 8 | $157 |
| Merck | 7 | $133 |
| Sunovion Pharmaceuticals Inc. | 11 | $132 |
| Novartis | 7 | $119 |
| United Therapeutics Corporation | 7 | $119 |
| Harmony Biosciences LLC | 5 | $113 |
| Intuitive Surgical | 1 | $99 |
| Advanced Respiratory, Inc | 4 | $71 |
| Covis Pharma GmbH | 3 | $70 |
| Abbott | 1 | $60 |
| Verona Pharma, Inc. | 2 | $57 |
| Inogen, Inc. | 3 | $53 |
| CSL Behring | 2 | $49 |
| Shionogi Inc | 2 | $45 |
| AbbVie | 2 | $44 |
| Phadia US Inc. | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| Jazz Pharmaceuticals Inc. | 2 | $34 |
| Johnson & Johnson | 2 | $33 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Grifols USA, LLC | 1 | $24 |
| Bayer | 1 | $23 |
| Mayne Pharma Commercial LLC | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Circassia Inc. | 1 | $16 |
| Gilead | 1 | $16 |
| Pfizer | 1 | $15 |
| Biogen | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$587
- BREZTRI$392
- FASENRA$381
- AIRSUPRA$278
- FLOWTRIEVER CATHETER, S$243
- CT THROMBECTOMY SYSTEM KIT$243
- FARXIGA$104
- SYMBICORT$104
How this compares
$8,918 in reported general payments places this provider in the 70th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 377 | $315,819 |
| ZemairaAlpha-1-Proteinase Inhibitor | 19 | $186,064 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 68 | $57,224 |
| Advair HfaFluticasone Propion/Salmeterol | 130 | $44,809 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 60 | $32,158 |
| Breo ElliptaFluticasone/Vilanterol | 45 | $30,441 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 61 | $30,361 |
| SymbicortBudesonide/Formoterol Fumarate | 82 | $24,577 |
| Spiriva RespimatTiotropium Bromide | 27 | $22,907 |
| Spiriva HandihalerTiotropium Bromide | 27 | $21,877 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 62 | $13,127 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 319 | $11,742 |
| EliquisApixaban | 18 | $10,873 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $10,037 |
| Wixela InhubFluticasone Propion/Salmeterol | 69 | $9,671 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,444 | $391,431523 claims |
| CSL BehringZemaira | $49 | $186,06419 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,429 | $87,090164 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $731 | $55,06587 claims |
| PfizerEliquis | $15 | $10,87318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Phoenix
- David BaratzPhoenix$2.2M
- James RossPhoenix$2M
- Rajat WaliaPhoenix$1.9M
- Mark GotfriedPhoenix$1.1M
- Abid KhokarPhoenix$321K
- Brian PorvinPhoenix$276K
- Tony HodgesPhoenix$262K
- Rajeev SaggarPhoenix$219K
- Ali SaeedPhoenix$213K
- Bhuvin BuddhdevPhoenix$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.